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Abstract
Background: DC-SIGN expressed by dendritic cells captures HIV-1 resulting in trans-infection of CD4
+ T-lymphocytes.
However, BSSL (bile-salt stimulated lipase) binding to DC-SIGN interferes with HIV-1 capture. DC-SIGN binding properties of
BSSL associate with the polymorphic repeated motif of BSSL exon 11. Furthermore, BSSL binds to HIV-1 co-receptor CXCR4.
We hypothesized that BSSL modulates HIV-1 disease progression and emergence of CXCR4 using HIV-1 (X4) variants.
Results: The relation between BSSL genotype and HIV-1 disease progression and emergence of X4 variants was studied
using Kaplan Meier and multivariate Cox proportional hazard analysis in a cohort of HIV-1 infected men having sex with men
(n=334, with n=130 seroconverters). We analyzed the association of BSSL genotype with set-point viral load and CD4 cell
count, both pre-infection and post-infection at viral set-point. The number of repeats in BSSL exon 11 were highly variable
ranging from 10 to 18 in seropositive individuals and from 5–17 in HRSN with 16 repeats being dominant (.80% carry at
least one allele with 16 repeats). We defined 16 to 18 repeats as high (H) and less than 16 repeats as low (L) repeat numbers.
Homozygosity for the high (H) repeat number BSSL genotype (HH) correlated with high CD4 cell numbers prior to infection
(p=0.007). In HIV-1 patients, delayed disease progression was linked to the HH BSSL genotype (RH=0.462 CI=0.282–0.757,
p=0.002) as was delayed emergence of X4 variants (RH=0.525, 95% CI=0.290–0.953, p=0.034). The LH BSSL genotype,
previously found to be associated with enhanced DC-SIGN binding of human milk, was identified to correlate with
accelerated disease progression in our cohort of HIV-1 infected MSM (RH=0.517, 95% CI=0.328–0.818, p=0.005).
Conclusion: We identify BSSL as a marker for HIV-1 disease progression and emergence of X4 variants. Additionally, we
identified a relation between BSSL genotype and CD4 cell counts prior to infection.
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Introduction
Millions have been infected worldwide with human immuno-
deficiency virus type-1 (HIV-1) but major differences exist between
individuals in infection risk and rate of disease progression. These
differences can be attributed in part to polymorphisms in host
genes encoding HIV-1 co-receptors such as CCR5 and CCR2 and
their ligands [1–5]. In addition, carrying human leukocyte antigen
(HLA) variants B27 or B57 is associated with slower HIV-1 disease
progression probably through HIV-1 specific CD8
+ T-lymphocyte
responses [6]. Knowledge of host genetic polymorphisms that
affect HIV-1 pathogenesis has helped with the successful
development of antiretroviral drugs and ways to modulate
beneficial immune responses. However, due to therapy failure
and incomplete virus suppression, there is a need for identification
of novel drug targets for the treatment of HIV-1 infection.
Among cell types targeted by HIV-1 are dendritic cells (DCs),
which play a central role in the protection against infections and
the activation of anti-microbial immune responses [7]. DCs
capture micro-organisms with the aim of degrading these
pathogens and presenting their antigens to resting T-lymphocytes
thereby activating adaptive immunity. Interaction between HIV-1
and DCs in all likelihood will occur at sites where mucosa is
breached when individuals are exposed to HIV-1. DCs efficiently
capture HIV-1 but captured HIV-1 partly escapes from
degradation and fully infectious virus particles are subsequently
presented to CD4
+ T-lymphocytes, thereby efficiently infecting
these target cells (trans-infection) [8].
DC-specific intercellular adhesion molecule-3 grabbing non
integrin (DC-SIGN) is the major HIV-1 binding receptor
expressed by immature DCs used for trans-infection. DC-SIGN
forms tetramers that bind terminal fucoses and high mannose
structures of ‘‘self’’ antigens and pathogen glycans and recognizes
a wide range of micro-organisms [9–12]. HIV-1 binds to DC-
SIGN and uses the pathogen receptor for trans-infection but, in
addition, DC-SIGN binding of HIV-1 results in modulation of DC
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formation of the infectious synapse between DC and T-
lymphocyte during trans-infection of CD4
+ T-lymphocytes with
HIV-1 and DC-SIGN binding of neutralized virus can result in
removal of neutralizing antibodies [14,15]. Human DC-SIGN
gene polymorphisms associate with the efficiency of HIV-1
transmission and the rate of disease progression and decreased
DC-SIGN expression in Rhesus Macaques is associated with
accelerated disease progression [16–18]. Whether DC-SIGN
ultimately limits or accelerates human disease progression remains
unclear, but obviously factors that competitively bind with HIV-1
to DC-SIGN will influence its function.
Among molecules that bind to DC-SIGN are mucin 6 in
seminal plasma and bile-salt stimulated lipase (BSSL, BSDL, CEL)
as well as mucin 1 identified in human milk [19–22]. BSSL is a
dimeric glycoprotein that is abundantly expressed in milk but, in
addition, is also expressed in blood [23,24]. The presence of DC-
SIGN blocking molecules in semen and breast milk may, at least in
part, influence HIV-1 transmission. This could help explain the
relatively low risk of HIV-1 infection during sex or breastfeeding
[25–28]. We previously identified that breast milks derived from
different mothers do not have equal DC-SIGN binding properties
suggesting mother-dependent protection levels for HIV-1 trans-
mission during breastfeeding [20]. In addition to DC-SIGN
binding, BSSL from blood can bind to chemokine receptor
CXCR4 [23,29] suggesting a potential supplementary role for
BSSL in HIV-1 pathogenesis.
Previous studies in our lab demonstrated that the DC-SIGN
binding capacity of milk is associated with variation in the BSSL
repeat domain [30]. Aim of the present investigation is to
determine the relation between variation in the BSSL genotype
(repeat domain) and HIV-1 infection and disease progression for
men having sex with men (MSM) participating in the Amsterdam
Cohort Studies on HIV infection and AIDS (ACS). This cohort
contains a high number of seroconverters (n=130) with a
relatively long duration of follow-up in the pre-combination
antiretroviral therapy (cART) era. Our research demonstrates that
both slow HIV-1 disease progression and emergence of delayed
CXCR4-using HIV-1 variants are correlated with homozygosity
for the high (H) repeat number BSSL genotype (HH). The BSSL
genotype that is dominant in patients with slow disease progression
(HH) corresponds to the main genotype observed in high risk
seronegative individuals. In addition, our study reveals that the
BSSL HH genotype correlates with high CD4 cell numbers prior
to infection. Our previous studies demonstrated that the LH BSSL
genotype is associated with enhanced DC-SIGN binding of human
milk [30]. In the present study on HIV-1 infected MSM we find
that this LH genotype is associated with accelerated disease
progression. Our research provides new insights in the role of
BSSL in HIV-1 pathogenesis with the potential for BSSL as a new
target for anti-HIV-1 drug development.
Results
Highly Exposed Seronegative Individuals and Slow
Progressing Seropositives have Comparable BSSL
Genotype Distributions
We genotyped the variable number of tandem repeat (VNTR)
domain of the BSSL gene in a cohort of 334 HIV-1 seropositive
men and 48 seronegative men with high risk behavior (high risk
seronegatives, HRSN). We found that the number of repeats in
this domain is highly variable ranging from 10 to 18 in seropositive
individuals (Figure 1A). Furthermore we observed that 82% within
this group carry at least one allele with 16 repeats, similar to the
situation in previously genotyped HIV-1 negative mothers in a
study on BSSL in human milk [30]. BSSL repeat numbers in
HRSN range from 5–17 with 85% having at least one allele with
16 repeats (Figure 1A). As compared to seropositives, a trend was
observed with HRSN having more frequently two alleles with 16
repeats (p=0.059).
We hypothesized that specific BSSL genotypes might provide a
certain level of protection against HIV-1 infection. To test this we
categorized individuals in this study based on the number of
repeats in BSSL exon 11. We pre-defined 16 to 18 repeats as high
(H) and less than 16 repeats as low (L) repeat numbers as
previously specified in our study of BSSL in human milk [30].
Individuals were categorized in 3 groups having either two low
(LL), one low and one high (LH) or two high repeat number alleles
(HH). HH is the major genotype whereas the LL genotype reaches
relatively low numbers in both HRSN and seropositives. HRSN
Figure 1. BSSL genotype distribution. (A) BSSL genotype distribu-
tion in high risk seronegative (HRSN, n=48) individuals and HIV-1
positive individuals (n=334). (B) Within the group of HIV-1 positives,
individuals with fast disease progression (progression to AIDS or CD4
cell count ,200 cells/ml within 3 years after seroconversion, n=21)
were compared to individuals with slow disease progression (time to
AIDS or CD4 cell count ,200 cells/ml is 10 years or longer after
seroconversion, n=63). We pre-defined 16–18 repeats as high (H) and
less than 16 repeats as low (L) repeat numbers. BSSL genotype
frequencies were compared for individuals with two low (LL), one low
and one high (LH) or two high repeat numbers (HH). BSSL genotype
distributions were different between individuals with slow disease
progression when compared to individuals with fast disease progres-
sion (Pearson Chi-square p=0.026). Additionally, HRSN were compared
to the whole study population of seropositive individuals (all) for the LL,
LH and HH genotypes (p=0.190).
doi:10.1371/journal.pone.0032534.g001
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(n=334) were not statistically different for the HH genotype
(Figure 1 B, p=0.190).
Disease progression was defined as the time between HIV-1
infection and diagnosis of AIDS or when CD4 counts dropped
below 200 cells/ml. Within the group of 334 seropositive
individuals we compared the BSSL genotype for individuals
progressing to AIDS within 3 years (fast progressors, n=21) with
individuals that remained AIDS free for 10 years or longer (slow
progressors, n=63) (Table 1). Figure 1B demonstrates that HRSN
men and seropositive men with slow disease progression have
similar BSSL genotype distributions.
BSSL Number of Repeats Correlates with HIV-1 Disease
Progression
We compared the number of repeats in the VNTR domain of
BSSL for fast progressors to that of slow progressors (Figure 1). The
distribution of genotypes is significantly different between the fast
and slow progressors (p=0.026) with slow progressors having
more frequently the HH genotype (Figure 1B, p=0.016). The
observed differences between fast and slow progressors did not
change significantly after excluding the two non-Europeans from
the slow progressor group (p=0.21 and p=0.12). Similar to the
situation with slow progressors, HRSN more frequently carry the
HH genotype when compared to fast progressors (p=0.028).
Using Kaplan Meier methods we observed a trend towards
differences in disease progression for patients with variable BSSL
genotypes (Figure 2A, log rank p=0.063). However, the effect of
the different BSSL genotypes on disease progression appeared non-
proportional and was observed from 6 years after seroconversion
onwards. Cox proportional hazard analysis from 6 years post-
seroconversion onwards demonstrates delayed disease progression
in patients with the HH genotype (HH vs LH: RH=0.436, 95%
CI=0.260–0.732, p=0.002; HH vs LL: RH=0.545, 95%
CI=0.271–1.095, p=0.089; Table 2). Subsequent multivariate
analysis from 6 years after seroconversion onwards demonstrated
that the observed differences are independent of disease
progression markers CCR5-D32, HLA-B57 and HIV-1 RNA
and CD4 levels at viral setpoint (Table 2).
Disease progression in patients with the LL genotype is not
significantly different from that in patients with the LH (p=0.501)
or HH (p=0.089) genotype, possibly due to the relatively low
number of individuals carrying this genotype (Table 2). Since the
LL genotype reaches relatively low frequencies we compared the
major (HH) genotype with the combined LL with LH genotype
(LL+LH) using Kaplan Meier methods. The results confirmed that
the HH genotype associates with delayed disease progression
(Figure 2B, log rank p=0.033). No differences in disease
progression were observed between groups until 6 years after
seroconversion (RH=0.967, 95% CI=0.667–1.401). However,
Cox proportional hazard analysis from 6 years post-seroconver-
sion onwards confirmed the delayed disease progression observed
in patients with the HH genotype (BSSL HH vs LL+LH,
RH=0.462 CI=0.282–0.757, p=0.002). Multivariate analysis
demonstrated that the predictive value of the HH BSSL genotype
for prolonged survival in this analysis was independent of the
CCR5-D32 and HLA-B57 genotype and low viral load at viral set-
point (RH=0.425, 95% CI=0.259–0.699, p=0.001). Inclusion
of ethnicity into the analysis did not alter the conclusions drawn
(RH=0.426, 95% CI=0.258–0.701, p=0.001).
We previously observed enhanced DC-SIGN binding properties
of human milk derived from mothers carrying the LH BSSL
genotype [30]. In the present study on HIV-1 infected MSM we
observed a significant difference in disease progression between
individuals with the LH and HH genotypes (Table 2). To test the
predictive value of the LH genotype for disease progression, we
combined the patients having the LL and HH genotypes and
compared disease progression forthesepatients withpatientshaving
the LH genotype. Using Kaplan Meier methods we observed that
the LH genotype is associated with accelerated disease progression
(Figure 3, log rank p=0.025). Cox proportional hazard analysis
from6 yearspost-seroconversion onwardsconfirmed theassociation
between LH genotype and accelerated disease progression
(RH=0.517, 95% CI=0.328–0.818, p=0.005).
Emergence of CXCR4-Using Variants is Associated with
the Number of Repeats in BSSL
DC-SIGN differentially enhances in-trans infection with CCR5
(R5) and CXCR4 using (X4) HIV-1 and BSSL protein interacts
with CXCR4 [23,31]. We hypothesized that size variation in the
BSSL exon 11 repeat domain could influence the time to X4
emergence during disease progression. Using Kaplan-Meier
methods we observed no significant effect of the three BSSL
genotypes on X4 emergence (Figure 2C, log rank p=0.106)
although patients with the HH genotype trended towards delay in
X4 emergence when compared to patients with the combined
LL+LH genotypes (Figure 2D, log rank p=0.085). However
Figures 2C and D suggested effects of the BSSL genotypes on X4
emergence appear non-proportional and were observed from 5
years post-seroconversion onwards. Cox proportional hazard
analysis from 5 years onwards demonstrated delayed emergence
of X4 variants in patients with the HH genotype (HH vs LL:
RH=0.418, 95% CI=0.194–0.901, p=0.026; HH vs LH:
RH=0.577, 95% CI=0.304–1.094, p=0.092).
Table 1. Characteristics of HIV-1 positive groups including fast progressors, slow progressors and whole group.
Status Age at SC
1 Number
infected Ethnicity Time to AIDS CD4 at viral set-point Viral load at set-point
Mean




(yrs) Range (yrs) Mean (cells/ml) SD
3 Mean (Log RNA) SD
3
Fast progresssors 36.2 24.0–54.0 21 21 0 2.3 0.5–3.0 306 166 5 0.7
Slow progressors 32.1 20.9–48.6 63 61 2 12.7 $10.0 631 235 3.7 0.7
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combined LL with LH genotype (LL+LH) using Cox proportional
hazard analysis we confirmed the protective effect for the HH
genotype (RH=0.525, 95% CI=0.290–0.953, p=0.034). When
comparing the LH genotype with the combined LL with HH
genotype (LL+HH) using Kaplan-Meier methods we observed no
effect on X4 emergence from the LH genotype (log rank
p=0.626). Multivariate analysis demonstrated that the predictive
value of the HH BSSL genotype for X4 emergence in this analysis
was independent of ethnicity (RH=0.541, 95% CI=0.297–0.985,
p=0.044). For the individuals remaining AIDS free and those
remaining X4 free we analyzed the relationship between clinical
progression to AIDS and X4 emergence within these groups. We
observed that 86% of the individuals remaining AIDS free also did
not develop X4 variants with no significant difference between the
HH and non-HH-genotypes (p=0.47).
BSSL Genotype is Associated with CD4 Cell Numbers in
Uninfected Individuals
We studied the relation between BSSL genotype and the HIV-1
viral load and CD4 cell count at viral setpoint, but did not find
significant differences between patients with different BSSL
genotypes (data not shown). Furthermore, we observed no
significant differences in CD4 decline from viral setpoint onwards
for the different genotypes (data not shown). However, within the
group of individuals for whom CD4 cell counts prior to infection
were known, we found that CD4 cell numbers prior to infection
were elevated within the group of individuals carrying the HH
Figure 2. AIDS-free and CXCR4-free survival from HIV-1 seroconversion with and without BSSL HH genotype. Kaplan Meier estimation
of patients with HH and non-HH (LL+LH) genotypes using (A+B) AIDS-free survival plotted for (A) all genotypes (LL n=47, LH n=139, HH n=139, log
rank p=0.063), (B) HH versus LL+LH genotypes (HH n=139, non-HH n=186) (log rank p=0.033) or (C+D) first detection of CXCR4-using HIV-1
variants as an endpoint for (C) all genotypes (LL n=41, LH n=126, HH n=127, log rank p=0.106) or (D) HH versus LL+LH genotypes (HH n=127,
non-HH n=167, log rank p=0.085).
doi:10.1371/journal.pone.0032534.g002
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with the combined LL with LH genotypes (LL+LH) confirmed the
elevated CD4 cell numbers prior to infection for individuals with
the HH genotype (p=0.007, Figure 4B).
Discussion
In this study we demonstrate that the rate of HIV-1 disease
progression is associated with BSSL polymorphisms in a cohort of
MSM. BSSL genes have either a high (H=16 to 18) or a low (L,16)
number of repeats in their variable number of tandem repeat (VNTR)
domain. Individuals can be categorized into having two low (LL), one
low and one high (LH) or two high (HH) repeat number BSSL alleles.
Our study reveals that uninfected individuals with the HH genotype
have elevated CD4 cell numbers compared to individuals carrying the
other genotypes. Once infected with HIV-1, MSM with the HH
Table 2. Cox proportional hazard analysis to AIDS or CD4 cell counts below 200 cells/ml blood.





4 (95%) p Number RH CI
4 (95%) p
BSSL HH vs LH 143 62 0.436 0.260–0.732 0.002 140 0.389 0.231–0.656 ,0.001
BSSL HH vs LL 99 35 0.545 0.271–1.095 0.089 98 0.539 0.267–1.086 0.084
BSSL LH vs LL 96 51 0.801 0.419–1.529 0.501 94 0.722 0.375–1.389 0.329
CCR5-D32 vs WT
5 168 74 0.457 0.251–0.832 0.010 166 0.451 0.247–0.826 0.010
HLA-B57 169 74 0.296 0.093–0.941 0.039 166 0.294 0.091–0.947 0.040
Viral RNA load (,10
4.5 copies/ml) 167 73 0.571 0.338–0.966 0.037 166 0.642 0.376–1.097 0.105
CD4 cells (.500 cells/ml) 163 72 0.681 0.426–1.090 0.110 - - - -
Cox proportional hazard analysis from 6 years after seroconversion to AIDS or CD4 cell counts below 200 cells per ml blood.
1number of individuals included in the analysis.
2number of individuals that reach the end point.
3relative hazard.
495% confidence interval.
5wild type CCR5 genotype.
doi:10.1371/journal.pone.0032534.t002
Figure 3. AIDS-free survival from HIV-1 seroconversion with
and without the BSSL LH genotype. Kaplan Meier estimation of
patients with LH and non-LH (LL+HH) genotypes using AIDS-free
survival plotted LH versus LL+HH genotypes (log rank p=0.025).
doi:10.1371/journal.pone.0032534.g003
Figure 4. BSSL HH genotype is associated with high CD4 cell
numbers pre-seroconversion. The relation between BSSL genotypes
and CD4 cell count before seroconversion for individuals with the (A)
LL, LH and HH genotypes (p=0.022) and (B) HH versus non-HH (LL+LH)
genotypes (p=0.007). Median values are indicated with a horizontal
line. NS: not significant, *: p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0032534.g004
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development of CXCR4-using HIV-1 variants.
Since differences in DC-SIGN binding properties of human
breast milk link to differently sized BSSL forms [20,30], we
hypothesized that BSSL expressed in blood behaves in a similar
fashion. We demonstrate here that variation in the number of
repeats encoded by the BSSL gene is linked to disease progression
in HIV-1 infected MSM. This could be the result of differences in
DC-SIGN binding by differently sized BSSL forms. The LH
genotype is associated with increased DC-SIGN binding capacity
of human milk [30] whereas in the present study we find this LH
genotype associated with accelerated disease progression. This
could imply that increased DC-SIGN blocking and thus decreased
DC-SIGN availability may accelerate disease progression similar
to the situation with low DC-SIGN expression in Rhesus
macaques. But care should be taken when translating the DC-
SIGN binding properties of BSSL from milk into those of BSSL in
blood since post-translational modifications such as glycosylation,
essential for DC-SIGN binding, may differ significantly.
In line with the effect of the BSSL genotype on progression to
AIDS, we observed a delay in the emergence of CXCR4-using
HIV-1 variants is associated with the HH genotype. Both disease
progression and emergence of CXCR4-using variants are delayed
in patients with the HH genotype, although this might in part
reflect the relation between the emergence of CXCR4-using
variants and disease progression [32].
Much of the damage related to HIV-1 infection, including rapid
depletion of CD4 cell numbers in the gut, occurs early in infection
whereas clinical manifestation are only detected years later.
Additionally, factors such as infecting viral strain phenotype,
CCR5-D32 and HLA genotypes can influence virulence during
the early stages of infection. This may explain why at viral setpoint
no significant differences were observed in CD4 cell numbers and
viral loads between carriers of different BSSL genotypes while
differences in CD4 cell numbers prior to seroconversion existed
and re-emergenced 6 years after seroconversion. Furthermore, if
BSSL indeed interacts with CXCR4 resulting in differential
emergence of CXCR4-using variants it is expected that the effects
appear later in disease.
DC-SIGN has been suggested to differentially enhance trans-
infection with R5 and X4 virus and the formation of infectious
synapses between DCs and T-lymphocytes and subsequent T-cell
stimulation [14,31]. Furthermore, CXCR4 not only acts as co-
receptor for CXCR4-using HIV-1 infection but is also involved in
the regulation of T-cell migration, proliferation and differentiation
[5,33,34]. BSSL interacts with both DC-SIGN and CXCR4
although not via the same structural domain [20,23]. Differences
in BSSL genotypes in all likelihood translate into BSSL proteins
with different DC-SIGN or CXCR4 binding properties and
related modulation of DC-SIGN and CXCR4 roles in disease
progression and CXCR4-using variant emergence. However,
more research is needed to identify whether disease progression
and emergence of CXCR4-using variants are similarly influenced
by these interactions. In addition, differences in the interaction
between BSSL and CXCR4 in individuals with different BSSL
genotypes might influence CD4 cell homeostasis.
The interaction between BSSL and CXCR4 was proposed to be
mediated through the V3 like domain of BSSL, which is not located
in the VNTR region [29]. This suggests that the potential influence
of BSSL size variation on the interaction between BSSL and
CXCR4 could be indirect, for example by influencing the
presentation of the V3 like domain to CXCR4. In addition, there
may also be structural constraints that influence plasma concentra-
tions of the different BSSL forms. In vitro studies with differently
sized BSSL proteins should provide a better insight in the role of the
VNTR in the interaction between BSSL and CXCR4.
The BSSL genotype distribution in HRSN was similar to that of
the slow progressors with a relative abundance of the HH
genotype. We suggest that the HH genotype provides partial
protection against infection possibly related to heightened
peripheral blood CD4 cell numbers in carriers of this genotype.
However, more research with higher numbers of HRSN included
is needed to further clarify the potential protective effect of BSSL
in protection against HIV-1 infection.
Taken together, we have identified BSSL as a marker for HIV-1
progression to AIDS and the emergence of CXCR4-using viruses
in HIV-1 infected MSM. Furthermore, we revealed an association
between BSSL genotypes and CD4 cell count in blood of
uninfected individuals. Further investigation should be aimed at
characterizing the effects of differently sized BSSL proteins on the
interaction between DC-SIGN and serum derived BSSL. In
addition, the binding between BSSL and CXCR4 should be
further characterized including the effect of such binding on
infection with CXCR4-using variants, CXCR4 signaling and
CD4
+ T-lymphocyte proliferation and migration. These studies
may ultimately increase our understanding of the role of BSSL in
HIV-1 pathogenesis.
Materials and Methods
Study participants and ethics statement
We studied HIV-1 infected men having sex with men (MSM) as
well as seronegative MSM with high risk behavior (high risk
seronegatives, HRSN). The MSM were enrolled in the Amster-
dam Cohort Studies on HIV infection and AIDS (ACS) between
October 1984 and March 1986 as previously described [35]. In
short, our study included 50 HRSN and HIV-1 seropositive MSM
and DNA was available for 335 HIV-1 infected and 48 HRSN.
HRSN had a HIV-seronegative follow-up despite unprotected
receptive anogenital sex with at least 2 different partners and/or a
reported episode of syphilis [36]. Among HIV-1 infected, 130
MSM seroconverted during follow-up and 205 tested positive for
HIV-1 antibodies at entry in the cohort of whom the date of
seroconversion can be reliably estimated. PCR failed with one of
the HIV-1 positive individuals and this sample was therefore
excluded from further analysis. The ACS has been conducted in
accordance with the ethical principles set out in the declaration of
Helsinki and written informed consent is obtained prior to data
collection. The study was approved by the Amsterdam Medical
Center institutional medical ethics committee.
Variables and definition of Disease Progression and
Emergence of CXCR4 Variants
Progression to AIDS and emergence of CXCR4 using variants
were studied. AIDS was defined as clinical AIDS or a CD4 cell
number below 200 cells/ml according to the 1993 CDC definition
[37]. CXCR4 using HIV-1 variants were detected by co-culture of
patient PBMC and MT2 cells as previously described [38].
Viral Load and CD4 Cell Count
Methods for viral load and CD4 cell counts determination from
individuals in the study population were described previously [35].
A value for CD4 cell count pre seroconversion was determined only
when three or more CD4 measurement time points were available.
CD4cellcount preseroconversionwasdefined bythemeanvalue of
all the available measurements when HIV-1 negative.
Viral load and CD4 cell count at viral set-point (2 years after
seroconversion) were included as disease progression markers.
HIV-1 Disease Links to BSSL Polymorphism
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at viral setpoint were performed from 2 years after seroconversion
onwards. HIV-1 set-point viral load below 10
4.5 copies per ml
plasma was pre-defined as low viral load and CD4 levels at viral
set-point above 500 cells per ml blood were pre-defined as high
CD4 cell numbers.
Genotyping PCR
Primers specific for BSSL were designed (forward primer: ACC
AAC TTC CTG CGC TAC TGG ACC CTC, reverse primer:
TGA TAC CAA GGC TCA TGG GAC GCT AAA AC)
containing a FAM label for detection. After initial denaturation
for 49 at 94uC the followingPCRprogram wasrunfor35 cycles:300
94uC,39 60uC, 19 72uC followed byan extended elongation for79at
72uC. The PCR product was mixed with the Genescan
TM –1 2 0 0
LIZH Standard (Applied Biosystems; catalog#: 4379950) and the
ABI 3100 capillary sequencer (Applied Biosystems) in Genescan
mode was used for PCR product size determination. Data was
analyzed using Genemapper software (Applied Biosystems).
Statistical Analysis
Kaplan Meier methods and multivariate Cox proportional
hazard analysis were used to study the relation between BSSL
genotype and progression to AIDS and the emergence of CXCR4-
using variants. Follow-up was calculated from the estimated date
of seroconversion until the earliest date of AIDS/emergence of
CXCR4 using variants (events), loss to follow-up, death or 1
January 1996 (censors). Patients dying of non AIDS-related causes
were censored at the time of death. Since the introduction of
cART in the Netherlands in 1996 will likely influence disease
course and emergence of CXCR4-using variants in infected
individuals the censor data were set at 1-1-1996 thereby excluding
post-cART era data points. Pearson Chi-square exact test was
used to study the relation of BSSL genotype distributions between
HRSN and seropositives as well as between fast and slow
progressors. First, overall differences in genotype distributions
were studied. When significant effects were found a posthoc test
was used to determine the source of the observed differences. The
effect of the genotype on CD4 cell count pre seroconversion, CD4
set-point and viral load set-point was analyzed using a non-
parametric ANOVA (rank transformed values). All Kaplan Meier,
Cox proportional hazard analyses and Pearson Chi-square exact
tests were carried out using SPSS (release 15, SPSS Inc.) and all
ANOVA analyses using Graphpad Prism software version 5. P-
value,0.05 was considered statistically significant.
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